Page last updated: 2024-11-12
fonsecinone a
Description
fonsecinone A: isolated from Aspergillus aculeatus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
fonsecinone A : A dimeric naphthopyran with formula C32H26O10, originally isolated from Aspergillus niger. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (15)
| Synonym |
|---|
| CHEBI:133759 |
| 5-hydroxy-10-(5-hydroxy-8,10-dimethoxy-2-methyl-4-oxo-4h-naphtho[1,2-b]pyran-9-yl)-6,8-dimethoxy-2-methyl-4h-naphtho[2,3-b]pyran-4-one |
| fonsecinone a |
| 95152-75-3 |
| bdbm50241853 |
| CHEMBL451678 , |
| 5-hydroxy-10-(5-hydroxy-8,10-dimethoxy-2-methyl-4-oxo-4h-naphtho(1,2-b)pyran-9-yl)-6,8-dimethoxy-2-methyl-4h-naphtho(2,3-b)pyran-4-one |
| 4h-naphtho(2,3-b)pyran-4-one, 5-hydroxy-10-(5-hydroxy-8,10-dimethoxy-2-methyl-4-oxo-4h-naphtho(1,2-b)pyran-9-yl)-6,8-dimethoxy-2-methyl- |
| 4422E9639H , |
| unii-4422e9639h |
| Q27896467 |
| 5-hydroxy-9-(5-hydroxy-6,8-dimethoxy-2-methyl-4-oxobenzo[g]chromen-10-yl)-8,10-dimethoxy-2-methylbenzo[h]chromen-4-one |
| 5-hydroxy-9-(5-hydroxy-6,8-dimethoxy-2-methyl-4-oxo-benzo[g]chromen-10-yl)-8,10-dimethoxy-2-methyl-benzo[h]chromen-4-one |
| DTXSID101317742 |
| (as)-fonsecinone a |
Roles (2)
| Role | Description |
|---|
| Aspergillus metabolite | Any fungal metabolite produced during a metabolic reaction in the mould, Aspergillus. |
| antibacterial agent | A substance (or active part thereof) that kills or slows the growth of bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (6)
| Class | Description |
|---|
| biaryl | An organic aromatic compound whose structure contains two aromatic rings or ring systems, joined to each other by a single bond. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
| cyclic ketone | |
| polyphenol | Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group. |
| naphtho-gamma-pyrone | Any naphthopyran whose skeleton consists of a naphathalene ring system ortho-fused to a gamma-pyrone. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (1)
Inhibition Measurements
Biological Processes (27)
Molecular Functions (11)
Ceullar Components (4)
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID332327 | Inhibition of human telomerase activity by TRAP assay | 2003 | Journal of natural products, Jan, Volume: 66, Issue:1
| New dimeric naphthopyrones from Aspergillus niger. |
| AID1777026 | Anticancer activity against cisplatin-resistant human A549 cells assessed as reduction in cell viability measured after 48 hrs in presence of cisplatin by MTT assay | | | |
| AID1651643 | Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess reagent based assay | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4
| Anti-inflammatory Metabolites from |
| AID332329 | Inhibition of human telomerase activity at 100 ug/mL by TRAP assay | 2003 | Journal of natural products, Jan, Volume: 66, Issue:1
| New dimeric naphthopyrones from Aspergillus niger. |
| AID402731 | Inhibition of xanthine oxidase | 2005 | Journal of natural products, Jul, Volume: 68, Issue:7
| Structural revision of aspernigrin A, reisolated from Cladosporium herbarum IFB-E002. |
| AID332328 | Inhibition of Taq polymerase in RNase treated human HT1080 cells at 100 ug/mL by PCR | 2003 | Journal of natural products, Jan, Volume: 66, Issue:1
| New dimeric naphthopyrones from Aspergillus niger. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.39 (24.57) | | Research Supply Index | 2.20 (2.92) | | Research Growth Index | 4.59 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |